+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Managing therapy and adverse effects with antihyperglycemic agents: a focus on metformin and acarbose

Managing therapy and adverse effects with antihyperglycemic agents: a focus on metformin and acarbose

Pharmacy Practice Management Quarterly 17(3): 21-31

Metformin and acarbose are novel antihyperglycemic agents indicated for the treatment of non-insulin-dependent diabetes mellitus. These agents offer new therapeutic options to control hyperglycemia that were previously unavailable. Common to both agents is a relatively high incidence of gastrointestinal adverse effects. Initiating therapy at a low dose and slowly titrating to therapeutic response may be the most effective way to minimize associated adverse effects. Recognition and proper management of these possible adverse effects can optimize therapy and maximize the potential for successful outcomes with these agents while limiting drug noncompliance.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046619221

Download citation: RISBibTeXText

PMID: 10173308

Related references

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycemic control versus metformin monotherapy due to a low rate of addition of antihyperglycemic agents. 2011

Comparison of metformin and acarbose monotherapy with combined metformin-acarbose treatment of patients with type 2 diabetes. Diabetes & Metabolism 29(Hors serie 2): 4S244, 2003

Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocrine Practice 19(5): 751-757, 2014

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Therapy 7(4): 659-678, 2016

Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). American Journal of Cardiology 89(11): 1308-1310, 2002

Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Research and Clinical Practice 102(1): 16-24, 2013

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Annals of Internal Medicine 154(10): 672-679, 2011

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obesity and Metabolism 16(10): 977-983, 2014

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Current Medical Research and Opinion 24(9): 2679-2690, 2008

Management of adverse effects of cancer therapy: nursing of a patient with acute symptoms probably due to the adverse effect of antineoplastic agents. Kangogaku Zasshi 49(2): 147-153, 1985

Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 32(6): E322, 2009

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19(3): 252-254, 1996

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Cmaj 183(16): E1213-E1220, 2011

Managing the adverse effects of bisphosphonate therapy on the jaw. Jaapa 22(11): 48-52, 2009

Managing the adverse effects of radiation therapy. American Family Physician 82(4): 381-8 394, 2010